Webster Bank’s Aurinia Pharmaceuticals AUPH Stock Holding History

Webster Bank’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,250	Closed	-$13.8K	–	659
2025 Q3	$13.8K	Buy	+1,250	New	+$13.7K	﹤0.01%	471

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Webster Bank's AUPH Position: Q4 2025 in Review

Webster Bank sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 1,250 shares — an estimated $13.8K sold.

Webster Bank first reported a position in AUPH in Q3 2025 and held it in 1 quarter. The position peaked at $13.8K in Q3 2025. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

Webster Bank reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Webster Bank sold 1,250 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $13.8K.
Webster Bank first reported a position in Aurinia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Webster Bank's Aurinia Pharmaceuticals position peaked at $13.8K in Q3 2025.
255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Webster Bank's 13F filing for Q4 2025, filed 23 Jan 2026.